Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Fulcrum Therapeutics Inc shares valued at $57,219 were sold by Tourangeau Greg on Mar 08 ’24. At $11.72 per share, Tourangeau Greg sold 4,884 shares. The insider’s holdings dropped to 11,807 shares worth approximately $0.11 million following the completion of this transaction.
Also, Sapir Alex purchased 43,360 shares, netting a total of over 492,028 in proceeds. Following the buying of shares at $11.35 each, the insider now holds 43,360 shares.
Before that, Tourangeau Greg had sold 210 shares from its account. In a trade valued at $695, the Principal Accounting Officer traded Fulcrum Therapeutics Inc shares for $3.31 each. Upon closing the transaction, the insider’s holdings decreased to 210 shares, worth approximately $0.14 million.
As published in their initiating research note from RBC Capital Mkts on March 13, 2024, Fulcrum Therapeutics Inc [FULC] has been an Outperform and the price target has been revised to $14. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in late September. As of August 23, 2023, H.C. Wainwright has increased its “Neutral” rating to a “Buy” for FULC. Earlier on August 22, 2023, Stifel upgraded its rating. Their new recommendation was “a Buy” for FULC stock which previously was a “a Hold”.
Analyzing FULC Stock Performance
During the last five days, there has been a drop of approximately -4.76%. Over the course of the year, Fulcrum Therapeutics Inc shares have jumped approximately 33.48%. Shares of the company reached a 52-week high of $13.70 on 03/06/24 and a 52-week low of $6.57 on 01/02/24. A 50-day SMA is recorded $9.43, while a 200-day SMA reached $5.82. Nevertheless, trading volume fell to 0.57 million shares from 0.36 million shares the previous day.
Support And Resistance Levels for Fulcrum Therapeutics Inc (FULC)
According to the 24-hour chart, there is a support level at 8.66, which, if violated, would cause prices to drop to 8.31. In the upper region, resistance lies at 9.48. The next price resistance is at 9.95. RSI (Relative Strength Index) is 39.61 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.56, which suggests the price will decrease in the coming days. Percent R is at 86.36%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Fulcrum Therapeutics Inc subject to short interest?
Stocks of Fulcrum Therapeutics Inc saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.83 million shares to 2.39 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 3.22 million shares. A decline of -34.73% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.06 of the overall float, the days-to-cover ratio (short ratio) decline to 3.06.
